These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26296596)

  • 21. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurolymphomatosis associated with Sézary syndrome.
    Bezier M; Reguiaï Z; Delaby P; Laroche L; Saïd G; Bernard P; Grange F
    Arch Dermatol; 2009 Mar; 145(3):294-6. PubMed ID: 19289760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained remission of Sézary syndrome.
    Bouwhuis SA; McEvoy MT; Davis MD
    Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
    Oliveira A; Lobo I; Alves R; Lima M; Selores M
    Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sézary syndrome without erythroderma.
    Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
    J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of bullous Sézary syndrome.
    Wu S; Jenkins F; Byrd R; Googe PB; Jolly PS
    Dermatol Online J; 2020 Apr; 26(4):. PubMed ID: 32621681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
    Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
    Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycosis fungoides/Sézary syndrome: report of an unusual case.
    Mehta A; Dhungel BM; Khan MF
    J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A modified staging classification for cutaneous T-cell lymphoma.
    Kashani-Sabet M; McMillan A; Zackheim HS
    J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sézary syndrome without erythroderma: A case report and review of published work.
    Kamijo H; Miyagaki T; Norimatsu Y; Shishido-Takahashi N; Kuzumi A; Asano Y; Sato S
    J Dermatol; 2019 Jan; 46(1):61-64. PubMed ID: 30379353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycosis fungoides: pathophysiology and emerging therapies.
    Duvic M; Foss FM
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S21-8. PubMed ID: 18086343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brentuximab-induced splinter nail haemorrhages in a patient with Sézary syndrome: A case report.
    Filipovic N; Likic R; Bulat V; Gašparov S; Delas Azdajic M
    Br J Clin Pharmacol; 2022 Aug; 88(8):3883-3886. PubMed ID: 35088431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemotherapy of cutaneous T-cell lymphomas with arotinoid].
    Mahrle G; Thiele B; Ippen H
    Dtsch Med Wochenschr; 1983 Nov; 108(46):1753-7. PubMed ID: 6605844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocosis fungoides--an update on a non-mycotic disease.
    Makdisi J; Friedman A
    J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
    Nguyen CN; Iyer SP; Duvic M; Barde PJ; Nair A; Routhu KV; Huen AO
    Invest New Drugs; 2023 Apr; 41(2):350-355. PubMed ID: 37004644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
    Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
    Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.
    Jang MS; Kang DY; Han SH; Park JB; Kim ST; Suh KS
    Australas J Dermatol; 2014 Feb; 55(1):e4-8. PubMed ID: 23190349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.